Global Blood Therapeutics Inc buy stratec
Summary
This prediction ended on 05.11.21 with a price of €33.71. With a performance of -7.61%, the BUY prediction for Global Blood Therapeutics Inc by stratec closed slightly in the red. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Global Blood Therapeutics Inc | - | - | - | - |
iShares Core DAX® | -0.531% | 3.824% | 15.862% | 16.424% |
iShares Nasdaq 100 | 2.338% | 3.067% | 21.901% | 35.414% |
iShares Nikkei 225® | 1.332% | 5.933% | 12.099% | -0.322% |
iShares S&P 500 | 1.181% | 3.042% | 22.103% | 38.834% |
Comments by stratec for this prediction
In the thread Global Blood Therapeutics Inc diskutieren
stratec stimmt der Buy-Einschätzung von klostergang zu
stratec stimmt am 14.12.2017 der Buy-Einschätzung von klostergang mit dem Kursziel 42,5$ zu.
Überschrift: Global Blood Th., mit Produktentwicklung für SCD und Hypoxämie#
14.12.2017 Global Blood Therapeutics (NASDAQ:GBT) price raised to $70 (83% upside) from $51 by Needham citing expected positive results from the Phase 3 HOPE study of voxelotor in sickle cell disease.
The FDA granted the company's lead candidate voxelotor Breakthrough Therapy for the treatment of sickle cell disease. It has a similar designation in Europe. Voxelotor is an oral once-daily therapy that works by increasing hemoglobin's affinity for oxygen.
In the thread Trading Global Blood Therapeutics Inc